Bausch & Lomb

R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Bangladesh Technical Education Board, Capital, PAD, Terumo, Health, Heart, Moyamoya disease, Research, Abbott Laboratories, Development, Patient, Worldwide, Venture round, Bausch & Lomb, ELITE, Series, Growth, Atomic mass, American Heart Association, BTK, Pharmaceutical industry

The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer.

Key Points: 
  • The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer.
  • The Series B financing was led by affiliates of Deerfield Management with participation from existing shareholders including 415 Capital and a strategic investor.
  • R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.
  • Commenting on the financing and the appointment of Mr. Owens, Jack Springer, Executive Chairman of R3 Vascular said, “On behalf of the R3 Vascular Board of Directors, we are very pleased to complete this exciting Series B financing and welcome Chris Owens as President and CEO.

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Retrieved on: 
Lunedì, Aprile 22, 2024
Poster, Marshal of France, International, Drug, Bausch & Lomb, Research, Depreciation, Mass meeting, Sale, NCX, IOP, Kowa, ARVO, Patent, Patient, COVID-19, Nitric oxide, Ocular hypertension, Glaucoma, BlackRock, Pharmaceutical industry

“Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.

Key Points: 
  • “Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.
  • The Nicox Board of Directors has co-opted Dr Gavin Spencer, CEO of Nicox, as a Board member with effect from April 8, 2024.
  • The debt restructuring amendment which was agreed in principle between Nicox and BlackRock and announced on February 28, 2024 was signed.
  • The audit procedures on the 2023 statutory financial statements of Nicox SA have been completed and the certification report is in the process of being issued.

Bausch + Lomb Announces First-Quarter 2024 Results

Retrieved on: 
Mercoledì, Maggio 1, 2024
Surgery, Medical Devices, Health, Pharmaceutical, Optical, News, Bausch, Care, Bausch & Lomb, Mar, Forecasting, Tax, Acquisition, EPS, Adjustment, Advertising, Ophthalmology, GAAP, Growth, Pharmaceutical industry

Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.

Key Points: 
  • Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.
  • Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $24 million, as compared to $34 million for the first quarter of 2023, a decrease of $10 million.
  • GAAP Earnings Per Share (“EPS”) Basic and Diluted attributable to Bausch + Lomb Corporation for the first quarter of 2024 was ($0.48), as compared to ($0.26) for the first quarter of 2023.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $0.07, as compared to $0.10 for the first quarter of 2023.

Heidelberg Engineering Showcases the Future of Imaging, Extending Its Capabilities With a Breadth of Research Technology

Retrieved on: 
Martedì, Aprile 30, 2024
Technology, Biotechnology, Health, Apps, Applications, Surgery, Optical, Artificial Intelligence, Research, Medical Devices, General Health, Health Technology, Science, Data Management, Clinical Trials, FDA, University, IOL, DICOM, AI, Bausch & Lomb, Biostatistics, Artificial intelligence, 3D, SRT, OCT, Algorithm, Epithelium, Corneal topography, Google Images, ARVO, ETM, Tomography, Medical imaging

For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.

Key Points: 
  • For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.
  • The groundbreaking, fully digital, surgical-visualization platform features next-generation image technology with state-of-the-art intraoperative OCT that will transform the modern OR.
  • "In 2025, Heidelberg Engineering is set to revolutionize basic vision science with the introduction of the Heidelberg CHAMELEON Imaging Research Platform," said Heidelberg Engineering Clinical Development Manager — Investigational Technologies, Dr. Sebastian Rausch.
  • Monday night, Heidelberg Engineering will host an award presentation for the winner of the Heidelberg Engineering Xtreme Research Award that recognizes aspiring researchers for their outstanding contribution to ophthalmic research.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Lunedì, Aprile 29, 2024
Vitamins, Supplements, Other Health, Retail, Other Science, Pharmaceutical, Research, Optical, Convenience Store, Medical Devices, Discount, Variety, Science, Clinical Trials, Medical Supplies, General Health, Surgery, Other Retail, Health, Specialty, Hydrogen, Verge, PAF, Frontiers Media, Efficacy, Safety, Trial of the century, Bausch & Lomb, MD, Erythritol, Development, Natural language, Convention (norm), Telecanthus, Research and development, Hosten, Toxicity, Comparison, Wood drying

The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.

Key Points: 
  • The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.
  • “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al.
  • “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al.
  • “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al.

Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Retrieved on: 
Giovedì, Aprile 25, 2024
Science, Other Science, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Lutein, Safety, Bausch & Lomb, D3, Trial of the century, Development, Research and development, Curcumin, Anxiety, Frontiers, OSDI, Ageing

The clinical study met both primary endpoints:

Key Points: 
  • The clinical study met both primary endpoints:
    Change from baseline at day 56 in ocular symptoms measured by OSDI score.
  • The study also met secondary endpoints, showing statistically significant improvements in tear-film break-up time (TBUT), osmolarity, ocular surface health and presence of an inflammatory marker.
  • “More than 150 million people experience dry eyes in the U.S.,” said Yehia Hashad, M.D., executive vice president, Research & Development and chief medical officer, Bausch + Lomb.
  • “This could represent a significant opportunity for consumers looking for options when it comes to long-lasting dry eye symptom relief.”

Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs

Retrieved on: 
Giovedì, Aprile 18, 2024
Medical Supplies, Other Health, Health, Philanthropy, Pharmaceutical, Optical, Other Philanthropy, Recycling, Medical Devices, Surgery, Environment, Safety, Bausch, Microplastics, Sustainability, Bausch & Lomb, Partnership, Water, OD, Contact, Patient, Dependent and independent variables, Contact lens

Contact lenses, eye care and lens care materials are typically not processed in standard recycling facilities due to their small size and the type of plastic used to manufacture them.

Key Points: 
  • Contact lenses, eye care and lens care materials are typically not processed in standard recycling facilities due to their small size and the type of plastic used to manufacture them.
  • Eye health packaging materials collected through the Bausch + Lomb recycling programs are used to create various post-consumer products like picnic tables and benches.
  • The Biotrue Eye Care Recycling program, which launched in April 2021, has collected nearly 825,000 eye drop single dose units, lens cases, lens solution caps, as well as all Biotrue-branded eye drop bottles2.
  • In addition to the U.S., Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts .

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

Retrieved on: 
Lunedì, Aprile 15, 2024
General Health, Pharmaceutical, Discount, Variety, Optical, Supermarket, Specialty, Medical Devices, Convenience Store, Retail, Surgery, Biotechnology, Medical Supplies, Health, Bausch & Lomb, Bausch

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024.
  • Bausch + Lomb will host a conference call and live webcast at 8 a.m.
  • ET to discuss the results and provide a business update.
  • All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

10th International TFOS Conference on the Tear Film and Ocular Surface: Basic Science and Clinical Relevance Announced

Retrieved on: 
Giovedì, Aprile 11, 2024
Education, Science, Tears, International, Santen Pharmaceutical, Tissue, Prevalence, Bausch & Lomb, Health, Abstract, Research, Research and development, Doctor of Philosophy, Conference, Development, Knowledge, Disease, TFOS, Relevance, Eye, Diagnosis, Pharmaceutical industry

BOSTON, April 11, 2024 /PRNewswire/ -- The Tear Film & Ocular Surface Society (TFOS), a world leader in eye health research and education, has announced the "10th International TFOS Conference on the Tear Film and Ocular Surface: Basic Science and Clinical Relevance" to be held from October 30th through November 2, 2024 at the Hilton Molino Stucky in Venice, Italy.

Key Points: 
  • BOSTON, April 11, 2024 /PRNewswire/ -- The Tear Film & Ocular Surface Society (TFOS), a world leader in eye health research and education, has announced the "10th International TFOS Conference on the Tear Film and Ocular Surface: Basic Science and Clinical Relevance" to be held from October 30th through November 2, 2024 at the Hilton Molino Stucky in Venice, Italy.
  • First, to assess the current knowledge and 'state of the art' research on the structure and function of tear film producing tissues, tears, and the ocular surface in both health and disease.
  • Although typically held every 4 years, the last TFOS Conference had to be canceled because of the global pandemic.
  • TFOS Conference sponsors include Bausch + Lomb (Title Sponsor), Dompé, Bruder, Espansione Group, Brill International, SINQI, Hangzhou Mocular, SIFI, Essiri Labs, Laboratorios Sophia, Théa, Intalight, and Santen Pharmaceutical.

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on: 
Mercoledì, Marzo 13, 2024
Mont Blanc, IOP, OCT, Whistler, Glaucoma, Ocular hypertension, Fluticasone, Database, Intraocular pressure, NCX, COVID-19, Patient, NDA, BlackRock, Sale, Bausch & Lomb, Therapy, Retina, Allergic conjunctivitis, Safety, Patent, Telecanthus, FDA, Corporation, Food, Pharmaceutical industry

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points: 
  • “Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
  • We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
  • In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
  • The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.